
    
      This study is a 12-week, randomised, parallel group, placebo controlled, multi-centre study.
      The primary objective is to evaluate the safety and tolerability of Nutrifriend Cachexia in
      patients with NSCLC. The secondary objectives of the study are to evaluate effects on body
      composition, muscle function, daily activity, inflammation, tumor growth, compliance,
      appetite and Quality of Life.
    
  